Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma

• Published in: Journal of Clinical and Experimental Hematopathology Vol. 60; no. 3; pp. 78 - 86
• Main Authors: Sakatani, Akio, Igawa, Takuro, Okatani, Takeshi, Fujihara, Megumu, Asaoku, Hideki, Sato, Yasuharu, Yoshino, Tadashi
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society for Lymphoreticular Tissue Research 01-01-2020; JSLRT
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD20 - analysis; CD79 Antigens - analysis; CD79a; classic Hodgkin lymphoma; Female; Hodgkin Disease - pathology; Humans; immunohistochemistry; Male; Middle Aged; Original; prognosis; Reed-Sternberg Cells - pathology; Survival Analysis; Young Adult; CD79a; immunohistochemistry; classic Hodgkin lymphoma; prognosis
• ISSN: 1346-4280; 1880-9952
• DOI: 10.3960/jslrt.20010

Classic Hodgkin lymphoma (CHL) is a lymphoid neoplasia characterized by the presence of large tumor cells, referred to as Hodgkin and Reed-Sternberg (HRS) cells, originating from B-cells in an inflammatory background. As the clinical significance of B-cell markers has yet to be fully elucidated, this study aimed to clarify the clinicopathological significance of CD79a in 55 patients with CHL. They were immunohistochemically divided into two groups, comprising of 20 CD79a-positive and 35 CD79a-negative patients. There was no significant correlation between CD79a and CD20 expression (rs = 0.125, P = 0.362). CD79a-positive patients were significantly older at onset (P = 0.011). There was no significant correlation between CD79a-positivity and clinical stage (P = 0.203), mediastinal involvement (P = 0.399), extranodal involvement (P = 0.749), or laboratory findings, including serum levels of lactate dehydrogenase (P = 1) and soluble interleukin-2 receptor (P = 0.251). There were significant differences in overall survival (OS) (P = 0.005) and progression-free survival (PFS) (P = 0.007) between CD79a-positive and CD79a-negative patients (5-year OS: 64.6% and 90.5%; 5-year PFS: 44.0% and 76.6%, respectively). Five patients in whom the majority (> 80%) of HRS cells expressed CD79a consisted of 4 males and 1 female aged between 52 and 81 years; 4 of them were in a limited clinical stage. We concluded that CD79a-positive CHL may have unique clinicopathological features.